CryoLife has received premarket approval from the US Food and Drug Administration (FDA) for its new Sologrip, a minimally invasive laser fiber-optic delivery system.
The Sologrip delivery system is a single-use, disposable handset intended to be used with the company’s Cardiogenesis transmyocardial revascularization (TMR) system.
CryoLife chairman, president and CEO Steven Anderson said that the company is pleased to receive FDA premarket approval for its updated Sologrip handset.
"We believe it will be well received by our customers and we look forward to continuing our efforts to increase adoption of this important treatment option for patients with angina," Anderson added.
Founded in 1984, CryoLife provides processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the US, and some countries in Europe, and Canada.